1. Soares et al., An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. Journal of Clinical Medicine, 2022.
2. Aporosa et al., De-mythologizing and re-branding of kava as the new 'world drug' of choice. Drug Science, Policy & Law, 2019.
3. FNs organisasjon for mat og landbruk (FAO), Verdens Helseorganisasjon (WHO): Kava: A review of the safety of traditional and recreational beverage consumption. Technical Report, 2016.
4. Kaeleigh, P. & Reynolds, E., Kava-Induced Ichthyosis. Journal of the Dermatology Nurses' Association, 2019.
5. Mathews et al., Inhibition of Human Cytochrome P450 Activities by Kava Extract and Kavalactones. Drug Metabolism and Disposition, 2002.
6. Sarris et al., Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology. Australia and New Zealand Journal of Psychiatry, 2011.
7. Steiner, G.G., The correlation between cancer incidence and kava consumption. Hawaii Medical Journal, 2000.
8. Prinsloo et al., Monoamine Oxidase Inhibition by Kavalactones from Kava (Piper Methysticum). Planta Medica, 2019.
9. Ligresti et al., Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB₁ receptor ligand. Pharmacological Research, 2012.
10. Chua et al., Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS One, 2016.
11. Sarris et al., Kava for generalized anxiety disorder. Australian and New Zealand Journal of Psychiatry, 2020.
12. Aporosa et al., The impact of traditional kava (Piper methysticum) use on cognition: Implications for driver fitness. Journal of Ethnopharmacology, 2022.
13. Cawte, J., Parameters of kava used as a challenge to alcohol. Australia and New Zealand Journal of Psychiatry, 1986.
14. Food Standards Australia & New Zealand. Kava (Piper methysticum) beverage for traditional
and recreational use. Risk and technical assessment, Urgent proposal P1057, 2021.